The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS OrphanPacific’s Orphan Drug Biz Faces Rough Going with Rising Costs
January 17, 2013
-
BUSINESS Domestic Drug Makers Working to Escape Dependence on Long-Listed Drugs through New Product Development
January 17, 2013
-
BUSINESS GMP Violations at Drug Substance Makers Prompt Series of New Voluntary Recalls of Generics; Stable Supplies Disrupted
January 16, 2013
-
ORGANIZATION JMA Vice Pres. Nakagawa Urges Pharmacies to Rigidly Check Medical Exam History of Epadel OTC Buyers
January 15, 2013
-
REGULATORY Focus May Be on Whether New Price Cutting Rule for Long-Listed Drugs Should Apply Only to Those Granted Premium
January 15, 2013
-
REGULATORY PMDA Probes How Insurance Pharmacies Utilize Drug Safety Information
January 11, 2013
-
BUSINESS Takeda to Pitch Lotriga for Patients with Residual Event Risks, Cultivate New Market
January 10, 2013
-
BUSINESS AbbVie to Focus on Specialty Care, “Not Interested” in Established Markets: CEO Winer
January 9, 2013
-
ORGANIZATION Efforts to Promote Generic Substitution Preferable to Cutting Prices of Long-Listed Drugs: Mr Sawai of JGA
January 8, 2013
-
BUSINESS “Appropriate Expressions” of Disease Awareness Ads Being Tested
January 7, 2013
-
ORGANIZATION Member Companies to Begin Enforcing New COP in FY2013: JPMA President Teshirogi
January 7, 2013
-
ORGANIZATION NHO to Review Calculation Method for Clinical Trial Costs
December 28, 2012
-
REGULATORY 2nd Abe Cabinet Inaugurated; Industry Awaits Decision on Perpetuation of Premium for New Drug Development
December 27, 2012
-
REGULATORY LDP to Finalize Tax Reform Outline for FY2013 by Late January
December 26, 2012
-
ORGANIZATION JMA to Discuss JPMA’s Transparency Guidelines with JPMA, Related Medical Organizations
December 25, 2012
-
REGULATORY MHLW to Establish a Venue for Discussions to Review Policies for OTC Switching of Lifestyle Disease Treatments
December 21, 2012
-
REGULATORY Osaka’s Healthcare Plan Highlights Differences in Definition of “Frequent Deliveries”
December 21, 2012
-
REGULATORY CSIMC Recommends New Rules on Reducing Prices of Long-Listed Drugs
December 21, 2012
-
REGULATORY MHLW to Revise and Consider Legislation of Ethical Guidelines for Clinical Research
December 20, 2012
-
REGULATORY Pharmaceutical Industry Welcomes Incoming Abe Administration
December 19, 2012
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…